Metabolic‐associated fatty liver disease is associated with severity of COVID‐19
Autor: | Qing-Feng Sun, Ting Yao Wang, Kenneth I. Zheng, Xiao Bo Wang, Hong Lei Ma, Ke Hua Pan, Jacob George, Yu-Jie Zhou, Yong-Ping Chen, Ming-Hua Zheng |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
medicine.medical_specialty
Hepatology business.industry Fatty liver Brief Definitive Report COVID-19 Disease Odds ratio medicine.disease medicine.disease_cause Obesity Confidence interval Coronavirus 03 medical and health sciences Pneumonia 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine medicine 030211 gastroenterology & hepatology business Cohort study |
Zdroj: | Liver International |
ISSN: | 1478-3231 1478-3223 |
DOI: | 10.1111/liv.14575 |
Popis: | The Corona Virus Disease 2019 (COVID‐19) pandemic has attracted increasing worldwide attention. While metabolic‐associated fatty liver disease (MAFLD) affects a quarter of world population, its impact on COVID‐19 severity has not been characterized. We identified 55 MAFLD patients with COVID‐19, who were 1:1 matched by age, sex and obesity status to non‐aged severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)‐infected patients without MAFLD. Our results demonstrate that in patients aged less than 60 years with COVID‐19, MAFLD is associated with an approximately fourfold increase (adjusted odds ratio 4.07, 95% confidence interval 1.20‐13.79, P = .02) in the probability for severe disease, after adjusting for confounders. Healthcare professionals caring for patients with COVID‐19 need to be aware that there is a positive association between MAFLD and severe illness with COVID‐19. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |